Hyloris Sets Out IPO Terms

Value-Added Medicines Specialist Eyes US 505(b)(2) Opportunities

Value-added medicines specialist Hyloris Pharmaceuticals has set out the financial terms for its IPO, aimed at providing funds to pursue US 505(b)(2) opportunities.

Euro
Hyloris has set out financial terms for its IPO • Source: Shutterstock

Belgian value-added medicines specialist Hyloris Pharmaceuticals has set out the financial terms for its initial public offering, the size of which could be as much as €71m ($80m).

Having at the start of this month announced the IPO – which will see the firm’s shares admitted to trading...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

Test

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

More from Business

uygukgigo

 
• By 

Test

Podcast test

 
• By